London-based hVivo to conduct so-called ‘challenge trials’ to try to achieve faster results
A London-based company has secured a UK government contract worth up to £10m to intentionally infect healthy young volunteers with Covid-19 to hasten the development of a vaccine.
So-called “challenge trials” have the potential to yield results more quickly than conventional vaccine field trials in which researchers must wait for participants to get infected in the real world. They can also be used to develop treatments and compare multiple vaccine candidates.
